Teva Pharmaceutical Industries Limited
TEVJF
$28.36
-$4.48-13.64%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.40% | 3.42% | 0.29% | 1.89% | -5.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.40% | 3.42% | 0.29% | 1.89% | -5.12% |
| Cost of Revenue | -2.51% | -0.32% | -3.08% | -1.66% | 3.33% |
| Gross Profit | 25.24% | 7.21% | 3.85% | 5.99% | -12.25% |
| SG&A Expenses | 17.65% | 5.30% | 2.13% | 3.72% | 5.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -440.00% | 350.00% | 600.00% | 111.76% | -86.11% |
| Total Operating Expenses | 3.41% | 1.94% | -1.94% | 0.73% | 3.34% |
| Operating Income | 40.28% | 8.44% | 9.42% | 7.42% | -26.78% |
| Income Before Tax | 136.44% | 301.87% | 183.27% | 162.42% | -148.62% |
| Income Tax Expenses | -1,492.86% | 210.14% | -112.38% | 242.31% | -31.71% |
| Earnings from Continuing Operations | 274.55% | 211.28% | 132.23% | 152.51% | -158.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | 97.87% | -- | -102.14% | 1,550.00% |
| Net Income | 321.20% | 199.08% | 133.33% | 253.96% | -146.87% |
| EBIT | 40.28% | 8.44% | 9.42% | 7.42% | -26.78% |
| EBITDA | 30.38% | 5.88% | 6.41% | 2.25% | -21.89% |
| EPS Basic | 318.17% | 197.87% | 132.93% | 251.86% | -146.37% |
| Normalized Basic EPS | 34.04% | 29.03% | 1.74% | -45.42% | -21.49% |
| EPS Diluted | 313.37% | 194.87% | 132.00% | 245.40% | -147.46% |
| Normalized Diluted EPS | 31.32% | 27.15% | 0.49% | -46.41% | -20.37% |
| Average Basic Shares Outstanding | 1.41% | 1.24% | 1.24% | 1.34% | 1.07% |
| Average Diluted Shares Outstanding | 3.53% | 2.74% | 2.47% | 3.21% | -0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |